98%
921
2 minutes
20
Breast cancer detection remains one of the most challenging problems in medical imaging. We propose a novel hybrid model that integrates Convolutional Neural Networks (CNNs), Bidirectional Long Short-Term Memory (Bi-LSTM) networks, and EfficientNet-B0, a pre-trained model. By leveraging EfficientNet-B0, which has been trained on the large and diverse ImageNet dataset, our approach benefits from transfer learning, enabling more efficient feature extraction from mammographic images compared to traditional methods that require CNNs to be trained from scratch. The model further enhances performance by incorporating Bi-LSTM, which allows for processing temporal dependencies in the data, which is crucial for accurately detecting complex patterns in breast cancer images. We fine-tuned the model using the Adam optimizer to optimize performance, significantly improving accuracy and processing speed. Extensive evaluation of well-established datasets such as CBIS-DDSM and MIAS resulted in an outstanding 99.2% accuracy in distinguishing between benign and malignant tumors. We also compared our hybrid model to other well-known architectures, including VGG-16, ResNet-50, and DenseNet169, using three optimizers: Adam, RMSProp, and SGD. The Adam optimizer consistently achieved the highest accuracy and lowest loss across the training and validation phases. Additionally, feature visualization techniques were applied to enhance the model's interpretability, providing deeper insight into the decision-making process. The Proposed hybrid model sets a new standard in breast cancer detection, offering exceptional accuracy and improved transparency, making it a valuable tool for clinicians in the fight against breast cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982387 | PMC |
http://dx.doi.org/10.1038/s41598-025-95311-4 | DOI Listing |
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Obstet Gynecol
July 2025
Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFIn Vitro Cell Dev Biol Anim
September 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.
S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.